TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
7.47
-0.06 (-0.80%)
Dec 24, 2025, 1:00 PM EST - Market closed
TransCode Therapeutics Employees
TransCode Therapeutics had 7 employees as of December 31, 2024. The number of employees decreased by 3 or -30.00% compared to the previous year.
Employees
7
Change (1Y)
-3
Growth (1Y)
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$3,876,275
Market Cap
6.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | -3 | -30.00% |
| Dec 31, 2023 | 10 | -9 | -47.37% |
| Dec 31, 2022 | 19 | 10 | 111.11% |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNAZ News
- 3 days ago - TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors - PRNewsWire
- 14 days ago - TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PRNewsWire
- 5 weeks ago - TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer - PRNewsWire
- 2 months ago - TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO - PRNewsWire
- 7 months ago - TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - PRNewsWire
- 8 months ago - TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - PRNewsWire
- 8 months ago - TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split - PRNewsWire
- 8 months ago - TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - PRNewsWire